Mirtazapin Alternova (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Alternova, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Alternova as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on depressive disorders by modulating noradrenergic and serotonergic pathways. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depressive episodes associated with major depressive disorder: alleviates core depressive features. - Depression with insomnia: helps improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome, especially with other serotonergic agents - Suicidal thoughts or behavior, particularly early in treatment - Severe hepatic dysfunction - Hyponatremia - Severe allergic reactions such as Stevens‑Johnson syndrome

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Assess depression severity: ensure accurate diagnosis and consider risk of suicidality. - Monitor weight: watch for significant weight gain and metabolic changes. - Evaluate for suicidal ideation: especially during the first weeks of treatment. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Antihypertensive drugs: potential additive hypotensive effect. - Anticholinergic medications: may exacerbate anticholinergic burden.